| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 24 | 2020 | 1795 | 1.970 |
Why?
|
| Kidney Failure, Chronic | 18 | 2020 | 2462 | 1.860 |
Why?
|
| Arteriovenous Shunt, Surgical | 7 | 2020 | 286 | 1.800 |
Why?
|
| Hematuria | 4 | 2017 | 233 | 1.580 |
Why?
|
| Nephrology | 4 | 2018 | 263 | 1.160 |
Why?
|
| Catheterization, Central Venous | 2 | 2019 | 527 | 0.920 |
Why?
|
| Liver Transplantation | 8 | 2024 | 2332 | 0.740 |
Why?
|
| Urinalysis | 3 | 2011 | 368 | 0.690 |
Why?
|
| Spin Labels | 1 | 2020 | 338 | 0.630 |
Why?
|
| Catheter-Related Infections | 2 | 2018 | 273 | 0.610 |
Why?
|
| Catheters, Indwelling | 2 | 2019 | 427 | 0.590 |
Why?
|
| Jugular Veins | 1 | 2018 | 210 | 0.580 |
Why?
|
| Diuresis | 3 | 2016 | 106 | 0.570 |
Why?
|
| Polyuria | 1 | 2016 | 37 | 0.560 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 219 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2021 | 2241 | 0.550 |
Why?
|
| Isotonic Solutions | 1 | 2016 | 116 | 0.550 |
Why?
|
| Magnesium Sulfate | 1 | 2016 | 73 | 0.550 |
Why?
|
| Waiting Lists | 2 | 2024 | 765 | 0.540 |
Why?
|
| Obstetric Labor, Premature | 1 | 2016 | 272 | 0.500 |
Why?
|
| Fellowships and Scholarships | 3 | 2018 | 1117 | 0.490 |
Why?
|
| Peritonitis | 1 | 2016 | 369 | 0.440 |
Why?
|
| Diabetic Nephropathies | 2 | 2020 | 973 | 0.430 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 312 | 0.420 |
Why?
|
| Photomicrography | 1 | 2011 | 71 | 0.380 |
Why?
|
| Bacteremia | 1 | 2018 | 979 | 0.380 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 809 | 0.350 |
Why?
|
| Mortality | 3 | 2019 | 2897 | 0.330 |
Why?
|
| Potassium | 10 | 1996 | 1311 | 0.320 |
Why?
|
| End Stage Liver Disease | 2 | 2024 | 352 | 0.310 |
Why?
|
| Risk Management | 1 | 2012 | 557 | 0.310 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 2007 | 15 | 0.300 |
Why?
|
| Kidney | 13 | 2023 | 7046 | 0.300 |
Why?
|
| Bacterial Infections | 1 | 2016 | 1406 | 0.290 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2007 | 61 | 0.290 |
Why?
|
| Erythropoietin | 1 | 2012 | 719 | 0.290 |
Why?
|
| Kidney Diseases | 3 | 2014 | 2093 | 0.280 |
Why?
|
| Hepatitis C, Chronic | 3 | 2023 | 1032 | 0.280 |
Why?
|
| Confusion | 2 | 2019 | 278 | 0.280 |
Why?
|
| Certification | 1 | 2010 | 418 | 0.270 |
Why?
|
| Hepatitis C | 4 | 2023 | 1583 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5491 | 0.260 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1934 | 0.250 |
Why?
|
| Clinical Competence | 2 | 2012 | 4777 | 0.250 |
Why?
|
| Living Donors | 2 | 2011 | 639 | 0.250 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 2318 | 0.250 |
Why?
|
| Hyponatremia | 1 | 2007 | 279 | 0.240 |
Why?
|
| Hepatectomy | 2 | 2024 | 558 | 0.240 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3576 | 0.230 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 1663 | 0.220 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 414 | 0.210 |
Why?
|
| Urologic Diseases | 2 | 2003 | 247 | 0.210 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2003 | 95 | 0.200 |
Why?
|
| Nephrectomy | 4 | 2005 | 934 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 3 | 6 | 1995 | 321 | 0.200 |
Why?
|
| Ascites | 1 | 2003 | 338 | 0.190 |
Why?
|
| Humans | 99 | 2024 | 760437 | 0.190 |
Why?
|
| Hypertension | 2 | 2021 | 8527 | 0.190 |
Why?
|
| Education, Medical, Graduate | 2 | 2012 | 2367 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 5 | 2020 | 2171 | 0.180 |
Why?
|
| Cholelithiasis | 1 | 2002 | 407 | 0.180 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2002 | 232 | 0.170 |
Why?
|
| Laparotomy | 1 | 2002 | 457 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 1995 | 452 | 0.170 |
Why?
|
| SEER Program | 1 | 2024 | 1449 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 3246 | 0.160 |
Why?
|
| Bartter Syndrome | 5 | 1990 | 23 | 0.150 |
Why?
|
| Enterococcus faecalis | 1 | 2019 | 246 | 0.150 |
Why?
|
| Translocation, Genetic | 8 | 1995 | 1388 | 0.150 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2019 | 109 | 0.150 |
Why?
|
| Kidney Transplantation | 11 | 2005 | 4226 | 0.150 |
Why?
|
| Retrospective Studies | 15 | 2024 | 80430 | 0.140 |
Why?
|
| Betamethasone | 1 | 2016 | 49 | 0.140 |
Why?
|
| Body Fluids | 1 | 2018 | 319 | 0.140 |
Why?
|
| Hepacivirus | 4 | 2023 | 1337 | 0.140 |
Why?
|
| Hyperkalemia | 5 | 1996 | 233 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2024 | 23953 | 0.140 |
Why?
|
| Risk Factors | 12 | 2024 | 74055 | 0.130 |
Why?
|
| Male | 56 | 2024 | 360035 | 0.130 |
Why?
|
| Creatinine | 3 | 2018 | 1898 | 0.130 |
Why?
|
| Bacteriophages | 1 | 2019 | 378 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2005 | 2025 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 2297 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2018 | 360 | 0.130 |
Why?
|
| Injections, Intramuscular | 1 | 2016 | 554 | 0.130 |
Why?
|
| Female | 60 | 2024 | 391875 | 0.120 |
Why?
|
| Homeostasis | 6 | 1996 | 3320 | 0.120 |
Why?
|
| Vascular Grafting | 1 | 2016 | 162 | 0.120 |
Why?
|
| Acute Kidney Injury | 5 | 2020 | 1925 | 0.120 |
Why?
|
| Pregnancy Complications | 2 | 2007 | 2946 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 1726 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 675 | 0.110 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2016 | 488 | 0.110 |
Why?
|
| Kidney Neoplasms | 9 | 1995 | 4241 | 0.110 |
Why?
|
| Aged | 28 | 2024 | 168840 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 4319 | 0.110 |
Why?
|
| Cause of Death | 1 | 2003 | 3686 | 0.110 |
Why?
|
| Adult | 44 | 2024 | 220781 | 0.100 |
Why?
|
| Risk | 2 | 2017 | 9605 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 36362 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2016 | 2217 | 0.100 |
Why?
|
| Hyperaldosteronism | 4 | 1980 | 244 | 0.100 |
Why?
|
| Proline | 1 | 2014 | 457 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 933 | 0.100 |
Why?
|
| Ribavirin | 1 | 2014 | 395 | 0.100 |
Why?
|
| Postnatal Care | 1 | 2014 | 262 | 0.100 |
Why?
|
| Time Factors | 9 | 2024 | 39947 | 0.100 |
Why?
|
| Epoetin Alfa | 1 | 2012 | 78 | 0.100 |
Why?
|
| Antihypertensive Agents | 2 | 2021 | 2018 | 0.100 |
Why?
|
| Survival Rate | 4 | 2024 | 12698 | 0.100 |
Why?
|
| Sex Factors | 4 | 2019 | 10538 | 0.100 |
Why?
|
| Aldosterone | 6 | 1996 | 866 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2024 | 2353 | 0.100 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 58859 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2011 | 81 | 0.090 |
Why?
|
| Recurrence | 4 | 2016 | 8466 | 0.090 |
Why?
|
| Test Taking Skills | 1 | 2010 | 10 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 753 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2016 | 2642 | 0.090 |
Why?
|
| Hemodynamics | 2 | 2020 | 4167 | 0.090 |
Why?
|
| Crystallization | 1 | 2011 | 533 | 0.090 |
Why?
|
| Hepatitis B, Chronic | 1 | 2014 | 410 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 1762 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2010 | 5866 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2014 | 920 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2020 | 8611 | 0.080 |
Why?
|
| United States | 10 | 2024 | 72202 | 0.080 |
Why?
|
| Quality Control | 1 | 2012 | 826 | 0.080 |
Why?
|
| Middle Aged | 35 | 2024 | 220382 | 0.080 |
Why?
|
| Medicare | 3 | 2024 | 6732 | 0.080 |
Why?
|
| Forecasting | 1 | 2018 | 2925 | 0.080 |
Why?
|
| Hematinics | 1 | 2012 | 282 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2012 | 3904 | 0.080 |
Why?
|
| Antithrombins | 1 | 2011 | 294 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1186 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1189 | 0.080 |
Why?
|
| Magnesium | 1 | 1992 | 809 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2011 | 3414 | 0.080 |
Why?
|
| Porphobilinogen | 1 | 2007 | 9 | 0.080 |
Why?
|
| ROC Curve | 1 | 2016 | 3571 | 0.080 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1989 | 85 | 0.080 |
Why?
|
| Registries | 1 | 2024 | 8216 | 0.070 |
Why?
|
| Panniculitis, Nodular Nonsuppurative | 1 | 1987 | 7 | 0.070 |
Why?
|
| Hemoptysis | 1 | 1989 | 152 | 0.070 |
Why?
|
| Pemphigoid, Bullous | 1 | 1989 | 114 | 0.070 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 362 | 0.070 |
Why?
|
| Familial Mediterranean Fever | 1 | 1987 | 65 | 0.070 |
Why?
|
| Problem-Based Learning | 1 | 2010 | 353 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 181 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2012 | 9309 | 0.070 |
Why?
|
| Biopsy | 2 | 2018 | 6765 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2011 | 855 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2016 | 6340 | 0.070 |
Why?
|
| Follow-Up Studies | 8 | 2016 | 39078 | 0.070 |
Why?
|
| Reoperation | 1 | 2016 | 4300 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2021 | 8479 | 0.070 |
Why?
|
| Hypertension, Portal | 1 | 2008 | 226 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 6525 | 0.060 |
Why?
|
| Salicylates | 1 | 1986 | 127 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14661 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 5 | 1995 | 3159 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5078 | 0.060 |
Why?
|
| Insurance Coverage | 2 | 2021 | 1934 | 0.060 |
Why?
|
| Comprehension | 1 | 2010 | 620 | 0.060 |
Why?
|
| Tissue Donors | 3 | 2024 | 2319 | 0.060 |
Why?
|
| Pancreas Transplantation | 3 | 1995 | 197 | 0.060 |
Why?
|
| Quality of Life | 3 | 2020 | 13338 | 0.060 |
Why?
|
| Antilymphocyte Serum | 2 | 1995 | 483 | 0.060 |
Why?
|
| Mental Recall | 1 | 2010 | 1213 | 0.060 |
Why?
|
| Program Development | 1 | 2010 | 1297 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 22097 | 0.060 |
Why?
|
| Acidosis | 1 | 1985 | 268 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2012 | 2493 | 0.060 |
Why?
|
| Altruism | 1 | 2005 | 208 | 0.050 |
Why?
|
| Pregnancy | 5 | 2016 | 29831 | 0.050 |
Why?
|
| Disease Progression | 1 | 2020 | 13484 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 3996 | 0.050 |
Why?
|
| Urography | 2 | 2003 | 316 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 2151 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 1212 | 0.050 |
Why?
|
| Prognosis | 4 | 2016 | 29551 | 0.050 |
Why?
|
| Donor Selection | 1 | 2024 | 230 | 0.050 |
Why?
|
| Prostaglandins | 2 | 1980 | 398 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2024 | 412 | 0.050 |
Why?
|
| Cohort Studies | 7 | 2018 | 41366 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2024 | 64591 | 0.050 |
Why?
|
| Ablation Techniques | 1 | 2024 | 248 | 0.050 |
Why?
|
| Platelet Aggregation | 3 | 1990 | 773 | 0.050 |
Why?
|
| Postoperative Complications | 4 | 2002 | 15627 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 3190 | 0.040 |
Why?
|
| Viremia | 1 | 2023 | 707 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2002 | 407 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2011 | 4438 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 2023 | 3066 | 0.040 |
Why?
|
| Adenocarcinoma | 3 | 1982 | 6330 | 0.040 |
Why?
|
| Perforin | 1 | 2019 | 167 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1981 | 590 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2019 | 189 | 0.040 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 505 | 0.040 |
Why?
|
| Informed Consent | 2 | 2005 | 1006 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2016 | 12932 | 0.040 |
Why?
|
| Employment | 1 | 2005 | 1114 | 0.040 |
Why?
|
| Lung Diseases | 1 | 1989 | 1909 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 413 | 0.040 |
Why?
|
| Karyotyping | 3 | 1993 | 1171 | 0.040 |
Why?
|
| Morbidity | 1 | 2003 | 1750 | 0.040 |
Why?
|
| Graft Survival | 3 | 2024 | 3806 | 0.040 |
Why?
|
| Educational Status | 1 | 2005 | 2518 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 325 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 1580 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2010 | 3880 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2357 | 0.040 |
Why?
|
| Acute Disease | 1 | 2007 | 7230 | 0.030 |
Why?
|
| Curriculum | 1 | 2010 | 3732 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2013 | 10075 | 0.030 |
Why?
|
| Probability | 1 | 2002 | 2476 | 0.030 |
Why?
|
| Pedigree | 4 | 1995 | 4586 | 0.030 |
Why?
|
| Potassium Chloride | 4 | 1988 | 230 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2002 | 2927 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 950 | 0.030 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 1988 | 65 | 0.030 |
Why?
|
| Hypokalemia | 3 | 1986 | 153 | 0.030 |
Why?
|
| Potassium, Dietary | 1 | 1995 | 103 | 0.030 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1976 | 109 | 0.030 |
Why?
|
| Motivation | 1 | 2005 | 2006 | 0.030 |
Why?
|
| Blood Platelets | 2 | 1990 | 2478 | 0.030 |
Why?
|
| Age Factors | 3 | 2019 | 18379 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15257 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 2 | 1986 | 181 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 3344 | 0.030 |
Why?
|
| Renal Artery Obstruction | 2 | 1991 | 219 | 0.030 |
Why?
|
| Prevalence | 1 | 2011 | 15698 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2002 | 2603 | 0.030 |
Why?
|
| Family | 1 | 2005 | 3189 | 0.030 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 1973 | 27 | 0.030 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 1995 | 305 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1996 | 666 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 3202 | 0.030 |
Why?
|
| Receptors, Adrenergic | 2 | 1986 | 155 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2019 | 782 | 0.030 |
Why?
|
| Ethanol | 1 | 2019 | 1324 | 0.030 |
Why?
|
| Insulin | 6 | 1996 | 6591 | 0.030 |
Why?
|
| Skin | 1 | 1987 | 4474 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 1494 | 0.030 |
Why?
|
| Hypoaldosteronism | 1 | 1992 | 7 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 6297 | 0.030 |
Why?
|
| Catecholamines | 3 | 1984 | 386 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2019 | 1232 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 5421 | 0.030 |
Why?
|
| Ammonia | 1 | 1973 | 237 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 59068 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12969 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 1973 | 159 | 0.020 |
Why?
|
| Pruritus | 3 | 1982 | 378 | 0.020 |
Why?
|
| Citrates | 1 | 1992 | 135 | 0.020 |
Why?
|
| Citric Acid | 1 | 1992 | 123 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2017 | 1139 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2021 | 1185 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1992 | 350 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 3923 | 0.020 |
Why?
|
| Prostaglandins E | 2 | 1982 | 169 | 0.020 |
Why?
|
| Chromosomes, Human, 1-3 | 2 | 1981 | 21 | 0.020 |
Why?
|
| Immunosuppressive Agents | 2 | 2011 | 4168 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2011 | 203 | 0.020 |
Why?
|
| Chromosomes, Human, 6-12 and X | 2 | 1981 | 77 | 0.020 |
Why?
|
| Alprostadil | 1 | 1990 | 86 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2024 | 3240 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1240 | 0.020 |
Why?
|
| Poisoning | 1 | 1992 | 252 | 0.020 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 1973 | 283 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1991 | 335 | 0.020 |
Why?
|
| Spironolactone | 2 | 1988 | 411 | 0.020 |
Why?
|
| Logistic Models | 2 | 2014 | 13240 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9745 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2002 | 9639 | 0.020 |
Why?
|
| Health Surveys | 1 | 2019 | 4056 | 0.020 |
Why?
|
| Renal Artery | 1 | 1991 | 351 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2000 | 2771 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 11096 | 0.020 |
Why?
|
| Prospective Studies | 5 | 2020 | 54339 | 0.020 |
Why?
|
| Liver | 3 | 2019 | 7531 | 0.020 |
Why?
|
| Syndrome | 1 | 1995 | 3267 | 0.020 |
Why?
|
| Desoxycorticosterone | 1 | 1988 | 46 | 0.020 |
Why?
|
| Alcoholism | 1 | 2019 | 1972 | 0.020 |
Why?
|
| Chromosome Fragility | 1 | 1988 | 16 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1976 | 2416 | 0.020 |
Why?
|
| Blood Glucose | 3 | 1993 | 6380 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1989 | 853 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 12054 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1976 | 2693 | 0.020 |
Why?
|
| Ultraviolet Therapy | 2 | 1979 | 84 | 0.020 |
Why?
|
| Length of Stay | 1 | 2002 | 6413 | 0.020 |
Why?
|
| Renin | 3 | 1982 | 639 | 0.020 |
Why?
|
| Gastroenterology | 1 | 2014 | 577 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7377 | 0.020 |
Why?
|
| Medicaid | 1 | 2021 | 2810 | 0.020 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1993 | 738 | 0.020 |
Why?
|
| Heart Failure | 1 | 2012 | 11653 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1745 | 0.020 |
Why?
|
| Alkalosis, Respiratory | 1 | 1987 | 20 | 0.020 |
Why?
|
| Uremia | 2 | 1979 | 201 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 10180 | 0.020 |
Why?
|
| Islets of Langerhans | 2 | 1991 | 1346 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1974 | 1373 | 0.020 |
Why?
|
| Mineralocorticoids | 1 | 1986 | 37 | 0.020 |
Why?
|
| Health Status | 1 | 2019 | 4071 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 1995 | 2571 | 0.020 |
Why?
|
| Salicylic Acid | 1 | 1986 | 62 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6230 | 0.020 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2008 | 172 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1988 | 575 | 0.020 |
Why?
|
| Absorption | 1 | 1985 | 243 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7380 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1986 | 361 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7817 | 0.020 |
Why?
|
| Angiography | 1 | 1991 | 1599 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2014 | 2846 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 15820 | 0.020 |
Why?
|
| Prednisone | 3 | 1995 | 1564 | 0.020 |
Why?
|
| Adolescent | 8 | 2019 | 88196 | 0.020 |
Why?
|
| Sympatholytics | 1 | 1984 | 82 | 0.020 |
Why?
|
| Fetal Death | 1 | 1987 | 435 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1988 | 592 | 0.020 |
Why?
|
| Half-Life | 1 | 1986 | 652 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1985 | 292 | 0.010 |
Why?
|
| Hematocrit | 1 | 1986 | 625 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1984 | 146 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2757 | 0.010 |
Why?
|
| Hodgkin Disease | 2 | 1972 | 1378 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1986 | 2498 | 0.010 |
Why?
|
| Cephalothin | 1 | 1983 | 35 | 0.010 |
Why?
|
| Indomethacin | 2 | 1982 | 326 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1986 | 1094 | 0.010 |
Why?
|
| Oncogenes | 1 | 1989 | 1223 | 0.010 |
Why?
|
| Thymine | 1 | 1963 | 68 | 0.010 |
Why?
|
| Ribonucleotides | 1 | 1963 | 114 | 0.010 |
Why?
|
| Glucagon | 3 | 1993 | 532 | 0.010 |
Why?
|
| Sodium | 3 | 1977 | 1589 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14565 | 0.010 |
Why?
|
| Leg | 1 | 1987 | 1089 | 0.010 |
Why?
|
| Gentamicins | 1 | 1983 | 251 | 0.010 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1982 | 87 | 0.010 |
Why?
|
| Arginine Vasopressin | 1 | 1982 | 125 | 0.010 |
Why?
|
| Alleles | 1 | 1993 | 6908 | 0.010 |
Why?
|
| Massachusetts | 1 | 2014 | 8826 | 0.010 |
Why?
|
| Diuretics | 1 | 1984 | 610 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3596 | 0.010 |
Why?
|
| Penicillins | 1 | 1984 | 406 | 0.010 |
Why?
|
| Muscles | 1 | 1986 | 1575 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20078 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 22121 | 0.010 |
Why?
|
| Azathioprine | 3 | 1995 | 356 | 0.010 |
Why?
|
| Kidney Concentrating Ability | 2 | 1983 | 34 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1993 | 2204 | 0.010 |
Why?
|
| Prostaglandin Antagonists | 1 | 1980 | 28 | 0.010 |
Why?
|
| Nucleotides | 1 | 1963 | 454 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1992 | 8522 | 0.010 |
Why?
|
| Glucose | 1 | 1991 | 4342 | 0.010 |
Why?
|
| Epinephrine | 2 | 1980 | 792 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12976 | 0.010 |
Why?
|
| Lectins | 3 | 1972 | 491 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1980 | 240 | 0.010 |
Why?
|
| Ischemia | 1 | 1988 | 1876 | 0.010 |
Why?
|
| RNA | 2 | 1993 | 2721 | 0.010 |
Why?
|
| Boston | 1 | 1992 | 9326 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1980 | 422 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2000 | 363 | 0.010 |
Why?
|
| Epoprostenol | 1 | 1979 | 246 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12429 | 0.010 |
Why?
|
| Animals | 7 | 2019 | 168253 | 0.010 |
Why?
|
| Ibuprofen | 1 | 1980 | 229 | 0.010 |
Why?
|
| Kinetics | 1 | 1986 | 6377 | 0.010 |
Why?
|
| Microbial Collagenase | 2 | 1968 | 112 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 10188 | 0.010 |
Why?
|
| Propranolol | 2 | 1980 | 489 | 0.010 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1980 | 291 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1986 | 4010 | 0.010 |
Why?
|
| Collagen | 3 | 1980 | 2637 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2014 | 4674 | 0.010 |
Why?
|
| Norepinephrine | 2 | 1996 | 897 | 0.010 |
Why?
|
| Thrombin | 1 | 1980 | 590 | 0.010 |
Why?
|
| Alkalosis | 1 | 1977 | 55 | 0.010 |
Why?
|
| Acid-Base Imbalance | 1 | 1976 | 41 | 0.010 |
Why?
|
| Tissue Survival | 1 | 1976 | 119 | 0.010 |
Why?
|
| Transplantation, Homologous | 5 | 1976 | 4808 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1980 | 1461 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1995 | 104 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7996 | 0.010 |
Why?
|
| Chromosome Aberrations | 2 | 1993 | 1771 | 0.010 |
Why?
|
| Pressoreceptors | 1 | 1975 | 99 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1984 | 1874 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 330 | 0.010 |
Why?
|
| Rats | 4 | 1984 | 23712 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1993 | 9267 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1980 | 1240 | 0.010 |
Why?
|
| Blood Volume | 1 | 1975 | 548 | 0.010 |
Why?
|
| Cell Line | 3 | 1993 | 15598 | 0.010 |
Why?
|
| Chromosome Mapping | 2 | 1993 | 4630 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1993 | 422 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 21322 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1995 | 778 | 0.010 |
Why?
|
| Hypertension, Renal | 1 | 1973 | 135 | 0.010 |
Why?
|
| DNA Probes | 1 | 1993 | 544 | 0.010 |
Why?
|
| Antibodies | 3 | 1990 | 2421 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1975 | 848 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 81402 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1974 | 286 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1993 | 263 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1974 | 719 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1974 | 384 | 0.010 |
Why?
|
| Child | 6 | 2011 | 80086 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 1545 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 9046 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1996 | 1197 | 0.010 |
Why?
|
| Lymphocytes | 3 | 1988 | 2610 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1993 | 436 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1983 | 2090 | 0.010 |
Why?
|
| Twins | 1 | 1972 | 339 | 0.010 |
Why?
|
| Gene Library | 1 | 1993 | 1059 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 417 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1976 | 1371 | 0.010 |
Why?
|
| Leukocytes | 2 | 1968 | 2024 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1990 | 866 | 0.010 |
Why?
|
| Clone Cells | 1 | 1993 | 1660 | 0.010 |
Why?
|
| C-Peptide | 1 | 1991 | 440 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1968 | 490 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1993 | 1647 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 1306 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1990 | 728 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 1627 | 0.000 |
Why?
|
| Skin Tests | 2 | 1968 | 637 | 0.000 |
Why?
|
| Aphidicolin | 1 | 1988 | 37 | 0.000 |
Why?
|
| Chromosome Fragile Sites | 1 | 1988 | 26 | 0.000 |
Why?
|
| Kidney Tubules | 2 | 1983 | 449 | 0.000 |
Why?
|
| Chromosome Banding | 1 | 1988 | 260 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1968 | 346 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1974 | 1559 | 0.000 |
Why?
|
| Hemagglutination Tests | 1 | 1967 | 76 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 4174 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1991 | 499 | 0.000 |
Why?
|
| Asthma | 1 | 1987 | 6195 | 0.000 |
Why?
|
| Nitrobenzenes | 1 | 1967 | 66 | 0.000 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1968 | 130 | 0.000 |
Why?
|
| Injections, Intradermal | 1 | 1967 | 116 | 0.000 |
Why?
|
| Diterpenes | 1 | 1988 | 171 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 1540 | 0.000 |
Why?
|
| Diet | 1 | 1984 | 8058 | 0.000 |
Why?
|
| Cadaver | 1 | 1970 | 1354 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1968 | 573 | 0.000 |
Why?
|
| Phentolamine | 1 | 1984 | 102 | 0.000 |
Why?
|
| Cattle | 2 | 1982 | 3849 | 0.000 |
Why?
|
| Phenylephrine | 1 | 1984 | 293 | 0.000 |
Why?
|
| Calcium | 1 | 1976 | 5726 | 0.000 |
Why?
|
| Immunization | 1 | 1967 | 1226 | 0.000 |
Why?
|
| Injections, Intravenous | 1 | 1984 | 1379 | 0.000 |
Why?
|
| Ouabain | 1 | 1982 | 247 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 2612 | 0.000 |
Why?
|
| Diabetes Insipidus | 1 | 1982 | 144 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1982 | 322 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1972 | 5491 | 0.000 |
Why?
|
| DNA Methylation | 1 | 1995 | 4383 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1982 | 661 | 0.000 |
Why?
|
| Urination | 1 | 1982 | 203 | 0.000 |
Why?
|
| Dehydration | 1 | 1982 | 216 | 0.000 |
Why?
|
| Sunlight | 1 | 1982 | 337 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 7208 | 0.000 |
Why?
|
| Peptides | 1 | 1991 | 4338 | 0.000 |
Why?
|
| Dinoprostone | 1 | 1982 | 597 | 0.000 |
Why?
|
| Electrophoresis | 2 | 1968 | 234 | 0.000 |
Why?
|
| Drug Hypersensitivity | 1 | 1967 | 917 | 0.000 |
Why?
|
| Carbon Isotopes | 2 | 1968 | 458 | 0.000 |
Why?
|
| Perfusion | 1 | 1982 | 1374 | 0.000 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1977 | 125 | 0.000 |
Why?
|
| Radioisotope Renography | 1 | 1976 | 61 | 0.000 |
Why?
|
| Adaptation, Biological | 1 | 1977 | 147 | 0.000 |
Why?
|
| Cells, Cultured | 2 | 1988 | 18955 | 0.000 |
Why?
|
| Nephrons | 1 | 1977 | 168 | 0.000 |
Why?
|
| Seasons | 1 | 1982 | 1518 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 384 | 0.000 |
Why?
|
| Suction | 1 | 1977 | 264 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2000 | 15476 | 0.000 |
Why?
|
| Sheep | 1 | 1977 | 1440 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1974 | 5815 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1993 | 5835 | 0.000 |
Why?
|
| Phototherapy | 1 | 1977 | 368 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1973 | 26280 | 0.000 |
Why?
|
| Connecticut | 1 | 1972 | 364 | 0.000 |
Why?
|
| Arteriosclerosis | 1 | 1976 | 1055 | 0.000 |
Why?
|
| Neoplasms | 1 | 2000 | 22083 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1977 | 1989 | 0.000 |
Why?
|
| Pancreas | 1 | 1977 | 1684 | 0.000 |
Why?
|
| Colon | 1 | 1977 | 1791 | 0.000 |
Why?
|
| Chromatography | 1 | 1968 | 189 | 0.000 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 1968 | 37 | 0.000 |
Why?
|
| Centrifugation | 1 | 1968 | 122 | 0.000 |
Why?
|
| Brucella abortus | 1 | 1968 | 14 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1981 | 10759 | 0.000 |
Why?
|
| Arthus Reaction | 1 | 1968 | 14 | 0.000 |
Why?
|
| gamma-Globulins | 1 | 1968 | 123 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1968 | 283 | 0.000 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1968 | 39 | 0.000 |
Why?
|
| Tularemia | 1 | 1968 | 42 | 0.000 |
Why?
|
| Acrylic Resins | 1 | 1968 | 135 | 0.000 |
Why?
|
| Viscosity | 1 | 1968 | 336 | 0.000 |
Why?
|
| Ethics, Medical | 1 | 1972 | 783 | 0.000 |
Why?
|
| Gels | 1 | 1968 | 419 | 0.000 |
Why?
|
| Glutathione | 1 | 1968 | 582 | 0.000 |
Why?
|
| ABO Blood-Group System | 1 | 1968 | 380 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1968 | 2560 | 0.000 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1968 | 579 | 0.000 |
Why?
|
| Cysteine | 1 | 1968 | 892 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1968 | 1397 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1968 | 731 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1968 | 1440 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1968 | 4234 | 0.000 |
Why?
|
| Neutrophils | 1 | 1968 | 3764 | 0.000 |
Why?
|
| Inflammation | 1 | 1968 | 10746 | 0.000 |
Why?
|
| Infant | 1 | 1968 | 36183 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1968 | 42209 | 0.000 |
Why?
|